Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019
Copyright © 2022 Moreno-Perez, Nuñez, Sandin-Rollan, Arrarte, Boix, Reus, Pinargote-Celorio, Ribes, Alfayate, Llorca-Santos, Martinez-Garcia, Chico-Sánchez and Merino..
Background: Carbohydrate antigen 125 (CA125) is an indicator of inflammation, immune response, and impaired cardiac function. The aim was to investigate whether CA125 behaves as a biomarker of severity and poor clinical outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19).
Methods: Serum CA125 [Elecsys CA125 II assay-(Roche Diagnostics GmbH)] was measured in stored biobank samples from COVID-19 hospitalized patients between 01 March 2020 and 17 October 2021. Multiple logistic regression models were built to explore the association between CA125 and clinical outcomes [in-hospital all-cause mortality, need for invasive mechanical ventilation (IMV), or non-invasive respiratory support (non-IRS)], estimating odds ratios (ORs; 95% CI). The gradient of risk of CA125 was evaluated by fractional polynomials.
Results: A total of 691 patients were included, median age of 63 years (50-76), men (57.2%), with high comorbidity. At admission, 85.8% had pneumonia. Median CA125 was 10.33 U/ml (7.48-15.50). The in-hospital mortality rate was 7.2%. After adjusting for confounding factors, CA125 ≥ 15.5 U/ml (75th percentile) showed an increased risk of death [OR 2.85(1.21-6.71)], as age ≥ 65 years, diabetes, and immunosuppression. Furthermore, CA125 as a continuous variable was positive and significantly associated with the risk of death after multivariate adjustment. The mean hospital stay of the patients with CA125 ≥ 15.5 U/ml was longer than the rest of the study population.
Conclusion: CA125 in the first 72 h of hospital admission seems a useful biomarker of mortality in hospitalized patients with moderate-severe COVID-19. If our findings are confirmed, the wide availability of this biomarker would make easy its widespread implementation in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Frontiers in cardiovascular medicine - 9(2022) vom: 01., Seite 941512 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moreno-Perez, Oscar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CA125 |
|---|
| Anmerkungen: |
Date Revised 08.11.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fcvm.2022.941512 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348517548 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348517548 | ||
| 003 | DE-627 | ||
| 005 | 20231226040433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fcvm.2022.941512 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348517548 | ||
| 035 | |a (NLM)36337886 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moreno-Perez, Oscar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.11.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Moreno-Perez, Nuñez, Sandin-Rollan, Arrarte, Boix, Reus, Pinargote-Celorio, Ribes, Alfayate, Llorca-Santos, Martinez-Garcia, Chico-Sánchez and Merino. | ||
| 520 | |a Background: Carbohydrate antigen 125 (CA125) is an indicator of inflammation, immune response, and impaired cardiac function. The aim was to investigate whether CA125 behaves as a biomarker of severity and poor clinical outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19) | ||
| 520 | |a Methods: Serum CA125 [Elecsys CA125 II assay-(Roche Diagnostics GmbH)] was measured in stored biobank samples from COVID-19 hospitalized patients between 01 March 2020 and 17 October 2021. Multiple logistic regression models were built to explore the association between CA125 and clinical outcomes [in-hospital all-cause mortality, need for invasive mechanical ventilation (IMV), or non-invasive respiratory support (non-IRS)], estimating odds ratios (ORs; 95% CI). The gradient of risk of CA125 was evaluated by fractional polynomials | ||
| 520 | |a Results: A total of 691 patients were included, median age of 63 years (50-76), men (57.2%), with high comorbidity. At admission, 85.8% had pneumonia. Median CA125 was 10.33 U/ml (7.48-15.50). The in-hospital mortality rate was 7.2%. After adjusting for confounding factors, CA125 ≥ 15.5 U/ml (75th percentile) showed an increased risk of death [OR 2.85(1.21-6.71)], as age ≥ 65 years, diabetes, and immunosuppression. Furthermore, CA125 as a continuous variable was positive and significantly associated with the risk of death after multivariate adjustment. The mean hospital stay of the patients with CA125 ≥ 15.5 U/ml was longer than the rest of the study population | ||
| 520 | |a Conclusion: CA125 in the first 72 h of hospital admission seems a useful biomarker of mortality in hospitalized patients with moderate-severe COVID-19. If our findings are confirmed, the wide availability of this biomarker would make easy its widespread implementation in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CA125 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a hospitalized | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a risk factors | |
| 700 | 1 | |a Nuñez, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Sandin-Rollan, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Arrarte, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Boix, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Reus, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Pinargote-Celorio, Hector |e verfasserin |4 aut | |
| 700 | 1 | |a Ribes, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Alfayate, Rocio |e verfasserin |4 aut | |
| 700 | 1 | |a Llorca-Santos, Maria Belen |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Garcia, Maria Angeles |e verfasserin |4 aut | |
| 700 | 1 | |a Chico-Sánchez, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Merino, Esperanza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in cardiovascular medicine |d 2014 |g 9(2022) vom: 01., Seite 941512 |w (DE-627)NLM255534736 |x 2297-055X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g day:01 |g pages:941512 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fcvm.2022.941512 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |b 01 |h 941512 | ||